These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 16109239

  • 21. [Mesalamine in the treatment of Crohn disease?].
    Nielsen OH, Thomsen OO.
    Ugeskr Laeger; 2005 Apr 11; 167(15):1656-7. PubMed ID: 15892345
    [No Abstract] [Full Text] [Related]

  • 22. [Possibilities of drug treatment in inflammatory intestinal diseases].
    van Hogezand RA, Lamers CB.
    Ned Tijdschr Geneeskd; 1994 Dec 17; 138(51):2536-40. PubMed ID: 7830801
    [No Abstract] [Full Text] [Related]

  • 23. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
    Rutgeerts P.
    Gut; 1999 Jul 17; 45(1):13-4. PubMed ID: 10498451
    [No Abstract] [Full Text] [Related]

  • 24. [Prevention of post-operative recurrence in Crohn's disease: a critical review of randomized controlled trials and meta-analyses of different therapeutic strategies].
    Margagnoni G, Clemente V, Aratari A, Fascì Spurio F, De Gregorio AM, Spagnolo A, Koch M, Papi C.
    Recenti Prog Med; 2013 Apr 17; 104(4):168-76. PubMed ID: 23748641
    [Abstract] [Full Text] [Related]

  • 25. Budesonide: a useful tool in the maintenance treatment of Crohn's disease?
    Schoon EJ.
    Neth J Med; 2007 Oct 17; 65(9):316-7. PubMed ID: 17954949
    [No Abstract] [Full Text] [Related]

  • 26. Mesalazine-induced aplastic anemia.
    Wiesen A, Wiesen J, Limaye S, Kaushik N.
    Am J Gastroenterol; 2009 Apr 17; 104(4):1063. PubMed ID: 19259075
    [No Abstract] [Full Text] [Related]

  • 27. [Mesalazine is effective in Crohn disease 1].
    Fallingborg J, Langholz E, Christensen LA, Munkholm P, Dahlerup JF.
    Ugeskr Laeger; 2005 Mar 14; 167(11):1307-8; author reply 1309. PubMed ID: 15830509
    [No Abstract] [Full Text] [Related]

  • 28. [Mesalazine is effective in Crohn disease 2].
    Quartarolo JP, Laegemidler F, Eskerod O.
    Ugeskr Laeger; 2005 Mar 14; 167(11):1308-9; author reply 1309. PubMed ID: 15830510
    [No Abstract] [Full Text] [Related]

  • 29. [Mesalazine is effective in Crohn disease].
    Quartarolo JP.
    Ugeskr Laeger; 2005 Apr 18; 167(16):1767. PubMed ID: 15898611
    [No Abstract] [Full Text] [Related]

  • 30. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease.
    Cottone M, Orlando A, Viscido A, Calabrese E, Cammà C, Casà A.
    Aliment Pharmacol Ther; 2003 Jun 18; 17 Suppl 2():38-42. PubMed ID: 12786611
    [Abstract] [Full Text] [Related]

  • 31. [Budesonide and inflammatory bowel disease].
    Gomollón F, Hinojosa J, Nos P.
    Gastroenterol Hepatol; 1999 Dec 18; 22(10):525-32. PubMed ID: 10650668
    [No Abstract] [Full Text] [Related]

  • 32. [Mesalazine is without clinical effect in patients with Crohn disease].
    Munck LK.
    Ugeskr Laeger; 2005 Jan 17; 167(3):302-3. PubMed ID: 15704804
    [No Abstract] [Full Text] [Related]

  • 33. [Chronic inflammatory bowel diseases. Do antihistaminics reduce the need for steroids?].
    MMW Fortschr Med; 2000 Jun 01; 142(22):59. PubMed ID: 10870388
    [No Abstract] [Full Text] [Related]

  • 34. [Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review].
    Thomsen OØ, Nielsen OH.
    Ugeskr Laeger; 2005 Aug 15; 167(33):3015-7. PubMed ID: 16109240
    [No Abstract] [Full Text] [Related]

  • 35. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
    Abreu MT.
    Nat Clin Pract Gastroenterol Hepatol; 2005 May 15; 2(5):210-1. PubMed ID: 16265201
    [No Abstract] [Full Text] [Related]

  • 36. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.
    González Carro P, Pérez Roldán F, Roncero García Escribano O, Lafuente R, Legaz Huidobro ML, Amigo Echenagusía A.
    J Clin Apher; 2006 Dec 15; 21(4):249-51. PubMed ID: 16607627
    [No Abstract] [Full Text] [Related]

  • 37. The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form.
    Prantera C, Bellinvia S.
    Dig Liver Dis; 2005 Feb 15; 37(2):135-6. PubMed ID: 15733528
    [No Abstract] [Full Text] [Related]

  • 38. [Improved treatment of Crohn's disease].
    Nau JY.
    Rev Med Suisse; 2005 May 04; 1(18):1241. PubMed ID: 15977716
    [No Abstract] [Full Text] [Related]

  • 39. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM, Schmidt D, Karlén P.
    Lakartidningen; 2005 May 04; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract] [Full Text] [Related]

  • 40. Update on the management of Crohn's disease.
    Buchner AM, Blonski W, Lichtenstein GR.
    Curr Gastroenterol Rep; 2011 Oct 04; 13(5):465-74. PubMed ID: 21792543
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.